Preclinical Evaluation of the RBD-Trimeric Vaccine: A Novel Approach to Strengthening Biotechnological Sovereignty in Developing Countries Against SARS-CoV-2 Variants.

Travel Medicine and Infectious Disease, Год журнала: 2025, Номер unknown, С. 102820 - 102820

Опубликована: Фев. 1, 2025

New immunogens against emerging new virus variants are essential for controlling variants. A preclinical study in which a receptor-binding domain (RBD) trimer was designed silico with information from the Beta (B.1.351), Omicron (BA.5), and Wuhan 1 variant. three-dimensional model of RBD-trimer made, synthesis based on RBD S protein Omicron. For experimental trials, 63 BALB/c mice were immunized divided into three groups: control (n=15), adjuvant (n=33). 81% (13/16), 90% (9/10), 85% (6/7) that received one dose, two doses, respectively, seroconverted. Significant statistical differences (p<0.001) found between group vaccinated RBD-trimer, adjuvant, group. The booster did not show significant (p>0.05. No inflammatory or cellular changes observed, highlighting safety vaccine candidate. Kinetics seroconversion 75% obtained doses tri-RBD. (P <0.0001). Applying candidate safe immunogenic SARS-CoV-2. This provides support country's biotechnological sovereignty its potential contribution to public health Colombia.

Язык: Английский

Commentary: Inactivated rabies virus vectored MERS-Coronavirus vaccine induces protective immunity in mice, camels, and alpacas

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 4, 2025

Induces Protective Immunity in Mice, Camels, and Alpacas (doi: 10.3389/fimmu.2022.823949), was recently published Frontiers Immunology (Section: Vaccines Molecular Therapeutics) (1). In this study, Chi et al. constructed a chimeric rabies virus (RABV) that expressed genetically modified S1 gene from the Middle East respiratory syndrome coronavirus (MERS-CoV), then evaluated its potential of virus-vectored vaccine after inactivation different animals. This study demonstrated inactivated S1-expressing RABV promising candidate against MERS-CoV for camelids. Here, we would like to express our scientific opinions on study.MERS is severe infectious disease caused by MERS-CoV, initially identified Saudi Arabia 2012 (2). Typical signs clinically include fever, cough shortness breath humans.MERS-CoV zoonotic virus, which has been dromedary camels several Member States East, Africa South Asia (3). There are number vaccines have reported including nucleic acid (4), subunit (5), nanoparticle (6), (7), even live-attenuated (8). Most designed using S protein, especially subunit.RABV virion bullet-shaped particle, containing single-stranded, negative-sense RNA genome, coding five proteins order: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), RNA-dependent polymerase (L). The can be reverse genetics, whereby foreign sequence inserted into genome rescuing replication-competent (9). RABV, if able expressing antigen induces immune responses vivo, play role development RABV-vectored vaccines, such as (10)(11), (12-13) replication-deficient (14)(15).The (IRVV) killed version antigen-expressing rescued cDNA clone genetics. an IRVV involves construction clone, contains recovery. More importantly, it must ensured target incorporated envelope (16). sequence-containing antigen-containing schematically shown Figure 1A andB, respectively. Some RABV-expressed antigens will processed, transported cell surface, finally, membrane-spanning proteins, embedded cellular envelope. Along with budding virion, viral (13,17). Compared vaccine, shows good safety profile evidenced neither mutation nor virulence reversion occurring IRVV-vaccinated animals.A albeit chemically inactivated, completely retain immunogenicity, eliciting not only anti-RABV response, but also more significantly, high-level antibodies pathogen. conducted al., rSRV9-MERS -inoculated mice, alpacas were independently secreting MERS-CoV-specific antibodies, implying ability inhibit infection animals.It widely RABVs potentials developing IRVVs (1,(12)(13)(17)(18)(19)(20)(21)(22)(23), whereas there still few disadvantages them. For example, may less efficient than immunogenicity. latter elicit so potent response single dose sufficient vaccination animals, former generally involved prime-boost (24)(25). order obtain at high level, regarded emerging virus. Although various anti-MERS-CoV reported, none them commercially available yet. field carried out their valuable guiding IRVV. conclusion, safe vaccine-inoculated induced vivo. Therefore, pave way future.

Язык: Английский

Rabies virus as vector for development of vaccine: pros and cons

Frontiers in Veterinary Science, Год журнала: 2024, Номер 11

Опубликована: Сен. 25, 2024

Язык: Английский